US pharmaceutical large Pfizer has entered into a worldwide licencing settlement with Innovent Biologics (Innovent), a Chinese language biopharmaceutical firm listed on the Hong Kong Inventory Change (HKEX), with the purpose of accelerating the event of modern oncology medicines, in response to a Might 28 announcement.
¬ Haymarket Media Restricted. All rights reserved.
Source link
#Pfizer #signs #potential #10.5bn #oncology #licencing #deal #Chinas #Innovent #FinanceAsia
